Loading...
XSTO
ERMA
Market cap2mUSD
Jul 10, Last price  
0.26SEK
1D
-4.14%
1Q
-37.04%
Jan 2017
-97.10%
IPO
-96.61%
Name

Enorama Pharma AB

Chart & Performance

D1W1MN
XSTO:ERMA chart
P/E
—
P/S
6.94
EPS
—
Div Yield, %
—
Shrs. gr., 5y
59.43%
Rev. gr., 5y
5.00%
Revenues
3m
-82.63%
1,383,2431,993,7783,991,2041,572,8905,256,0117,610,7172,146,00011,036,0006,847,0001,358,00015,768,0002,739,000
Net income
-75m
L+71.53%
-20,000-656,000-7,836,114-8,755,754-16,339,339-24,721,571-23,901,000-28,544,000-41,780,000-44,613,000-43,806,000-75,139,000
CFO
-59m
L+65.99%
307,000480,000-6,114,487-6,666,545-13,360,169-26,563,507-22,998,000-30,164,000-32,958,000-41,349,000-35,702,000-59,261,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.
URL
https://www.enorama.se/
IPO date
Jun 10, 2016
Employees
9
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT